Molecular classification of diffuse gliomas

Area of Science:

• Neuro-oncology
• Molecular Pathology
• Cancer Biomarkers

Background:

• Gliomas exhibit molecular heterogeneity, influencing treatment response.
• Previous classification by Verhaak et al. (2010) utilized molecular subtypes.
• Immunohistochemistry (IHC) offers a potential method for subtype classification.

Purpose of the Study:

• To determine if gliomas can be molecularly subtyped using IHC.
• To assess the prognostic and predictive significance of these subtypes and individual markers.
• To identify correlations between molecular markers in glioma subtypes.

Main Methods:

• Included 146 glioblastomas (GBMs) and 26 diffuse astrocytomas (DAs).
• Tested samples for PDGFRA, IDH1 R132H, CD44, p53, Ki-67, p21, and p27 expression via IHC.
• Analyzed prognostic and predictive roles of subtypes and markers, and marker correlations.

Main Results:

• Gliomas were successfully subtyped by IHC: 50% GBMs were proneural, 18.5% mesenchymal; 92.3% DAs were proneural.
• Molecular subtypes had predictive, not prognostic, roles; proneural and mesenchymal subtypes benefited from chemotherapy and radiotherapy.
• IDH1 R132H was the only significant prognostic marker for GBMs; PDGFRA and Ki-67 were prognostic in DAs.

Conclusions:

• IHC is effective for molecular subtyping of gliomas, identifying proneural and mesenchymal subtypes.
• Mesenchymal and proneural subtypes predict response to combined chemotherapy and radiotherapy.
• IDH1 R132H mutation status is a crucial prognostic indicator in glioblastomas.